Get the Stockscreener App
2.43
2.10%
+0.05
Pre-market:
2.52
0.09
+3.70%
Vivos Therapeutics Inc stock is currently priced at $2.43, with a 24-hour trading volume of 50,014.
It has seen a +2.10% increased in the last 24 hours and a -19.27% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.46 pivot point. If it approaches the $2.29 support level, significant changes may occur.
Previous Close:
$2.38
Open:
$2.38
24h Volume:
50,014
Market Cap:
$7.25M
Revenue:
$14.50M
Net Income/Loss:
$-15.41M
P/E Ratio:
-3.4225
EPS:
-0.71
Net Cash Flow:
$-13.04M
1W Performance:
-3.95%
1M Performance:
-19.27%
6M Performance:
-30.17%
1Y Performance:
+648.38%
1D Range:
$2.38
$2.50
52W Range:
$0.18
$48.79
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
844-672-4357
Address
7921 Southpark Plaza, Suite 210, Littleton
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
GlobeNewswire Inc.
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
GlobeNewswire Inc.
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
GlobeNewswire Inc.
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
GlobeNewswire Inc.
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Vivos Therapeutics Inc (VVOS) Revenue 2024
VVOS reported a revenue (TTM) of $14.50 million for the quarter ending September 30, 2023, a -11.93% decline year-over-year.
Vivos Therapeutics Inc (VVOS) Net Income 2024
VVOS net income (TTM) was -$15.41 million for the quarter ending September 30, 2023, a +38.72% increase year-over-year.
Vivos Therapeutics Inc (VVOS) Cash Flow 2024
VVOS recorded a free cash flow (TTM) of -$13.04 million for the quarter ending September 30, 2023, a +40.24% increase year-over-year.
Vivos Therapeutics Inc (VVOS) Earnings per Share 2024
VVOS earnings per share (TTM) was -$13.10 for the quarter ending September 30, 2023, a +55.44% growth year-over-year.
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. The company offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. It also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
1.60%
0.30%
Cap:
|
Volume (24h):